-
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
Niemann, C. U., Dubois, J., Nasserinejad, K., da Cunha-Bang, C., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., van der Kevie-Kersemaekers, A.-M. F., Dobber, J. A., Poulsen, C. B., Razawy, W., Hollestein, R., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J. & Brieghel, C. & 5 others, , 12 Aug 2025, In: Blood. 9, 15, p. 3665-3675Research output: Contribution to journal › Article › Academic › peer-review
-
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL
Kater, A. P., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Langerak, A. W., Chyla, B., Popovic, R., Jiang, Y., Millen, R., Lefebure, M. & Thadani-Mulero, M. & 2 others, , 5 Jun 2025, In: Blood. 145, 23, p. 2733-2745Research output: Contribution to journal › Article › Academic › peer-review
-
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Kater, A. P., Arslan, Ö., Demirkan, F., Herishanu, Y., Ferhanoglu, B., Diaz, M. G., Leber, B., Montillo, M., Panayiotidis, P., Rossi, D., Skarbnik, A., Tempescul, A., Turgut, M., Mellink, C. H., van der Kevie-Kersemaekers, A.-M. F., Lanham, S., Sale, B., del Rio, L., Popovic, R. & Chyla, B. J. & 7 others, , 1 Apr 2024, In: The Lancet Oncology. 25, 4, p. 463-473 11 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
